Literature DB >> 23715879

Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study.

Fabio Pacelli1, Giacomo Cusumano, Fausto Rosa, Daniele Marrelli, Mariantonietta Dicosmo, Chiara Cipollari, Alberto Marchet, Stefano Scaringi, Stefano Rausei, Alberto di Leo, Franco Roviello, Giovanni de Manzoni, Donato Nitti, Francesco Tonelli, Giovanni Battista Doglietto.   

Abstract

IMPORTANCE: The role of multivisceral resection, in the setting of locally advanced gastric cancer, is still debated. Previous studies have reported a higher risk for perioperative morbidity and mortality, with limited objective benefit in terms of survival. Conversely, recent studies have shown the feasibility of enlarged resections and the potential advantage of extended resection for clinical stage T4b gastric adenocarcinoma with good long-term results.
OBJECTIVE: To analyze the role of multivisceral resection for locally advanced gastric cancer with particular attention to the brief and long-term results and to the prognostic value of clinical and pathologic factors.
DESIGN: Prospective multicenter study using data from between January 1, 1995, and December 31, 2008. SETTINGS: Seven Italian surgery centers. PATIENTS: A total of 2208 patients underwent curative resections for gastric carcinoma at the centers. Among them, 206 patients presented with a clinical T4b carcinoma. One hundred twelve underwent a combined resection of the adjacent organs with a gastrectomy owing to suspicion or direct invasion of these organs by the gastric cancer. MAIN OUTCOMES AND MEASURES: Clinical and pathologic variables were prospectively collected and the feasibility and efficacy of multivisceral resection for locally advanced clinical T4b gastric cancer were assessed.
RESULTS: Postoperative mortality and complication rates of patients who underwent a gastrectomy with a combined resection of the involved organs were 3.6% and 33.9%, respectively. Pathologic factors revealed that the nodal involvement was present in about 89.3% of patients and the mean (SD) number of pathologic lymph nodes was 14.8 (16.6). The overall 5-year survival rate was 27.2%. The completeness of resection and lymph node invasion represent independent prognostic parameters at multivariate analysis. CONCLUSIONS AND RELEVANCE: Our study indicates that patients undergoing extended resections experience acceptable postoperative morbidity and mortality rates, and an en bloc multivisceral resection should be performed in patients when a complete resection can be realistically obtained and when lymph node metastasis is not evident.

Entities:  

Mesh:

Year:  2013        PMID: 23715879     DOI: 10.1001/2013.jamasurg.309

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  21 in total

1.  Emergency Radical Gastrectomy with Pancreatico-duodenectomy for a Recent Onset Perforation of Locally Advanced Gastric Cancer with Pancreatic Head Involvement-Exceptional but a Definite Option.

Authors:  Mufaddal Kazi; Shailesh V Shrikhande; Vikram A Chaudhari; Sagar Kurunkar; Manish S Bhandare
Journal:  Indian J Surg Oncol       Date:  2020-08-29

2.  Evaluation of Clavien-Dindo classification in patients undergoing total gastrectomy for gastric cancer.

Authors:  Junfeng Zhou; Peiwu Yu; Yan Shi; Bo Tang; Yingxue Hao; Yongliang Zhao; Feng Qian
Journal:  Med Oncol       Date:  2015-03-19       Impact factor: 3.064

Review 3.  Multimodal treatment of gastric cancer in the west: Where are we going?

Authors:  Daniele Marrelli; Karol Polom; Giovanni de Manzoni; Paolo Morgagni; Gian Luca Baiocchi; Franco Roviello
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

4.  Extended Gastrectomy for T4b Gastric Adenocarcinoma: Single-Surgeon Experience.

Authors:  Mushegh А Sahakyan; Artak Gabrielyan; Hmayak Petrosyan; Shushan Yesayan; Sevak S Shahbazyan; Arthur M Sahakyan
Journal:  J Gastrointest Cancer       Date:  2020-03

5.  Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer.

Authors:  Kazuhito Mita; Hideto Ito; Toshio Katsube; Ayaka Tsuboi; Nobuyoshi Yamazaki; Hideki Asakawa; Takashi Hayashi; Keiichi Fujino
Journal:  J Gastrointest Surg       Date:  2017-09-22       Impact factor: 3.452

6.  Associated liver and multivisceral resections: should we extend the frontiers of resectability?

Authors:  Martin de Santibañes; Agustin Dietrich; Virginia Cano Busnelli; Juan Pekolj; Guillermo Ojea Quintana; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2015-02-17

7.  Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center.

Authors:  J C Molina; A Al-Hinai; A Gosseling-Tardif; P Bouchard; J Spicer; D Mulder; C L Mueller; L E Ferri
Journal:  J Gastrointest Surg       Date:  2018-04-16       Impact factor: 3.452

8.  Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma.

Authors:  Shumei Yan; Fan He; Rongzhen Luo; Huini Wu; Mayan Huang; Chunyu Huang; Yong Li; Zhiwei Zhou
Journal:  Tumour Biol       Date:  2015-11-26

9.  Risk factors associated with complication following gastrectomy for gastric cancer: retrospective analysis of prospectively collected data based on the Clavien-Dindo system.

Authors:  Kyung-Goo Lee; Hyuk-Joon Lee; Jun-Young Yang; Seung-Young Oh; Slava Bard; Yun-Suhk Suh; Seong-Ho Kong; Han-Kwang Yang
Journal:  J Gastrointest Surg       Date:  2014-05-13       Impact factor: 3.452

10.  Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience.

Authors:  Fausto Rosa; Daniele Marrelli; Paolo Morgagni; Chiara Cipollari; Giovanni Vittimberga; Massimo Framarini; Luca Cozzaglio; Corrado Pedrazzani; Stefano Berardi; Gian Luca Baiocchi; Franco Roviello; Nazario Portolani; Giovanni de Manzoni; Guido Costamagna; Giovanni Battista Doglietto; Fabio Pacelli
Journal:  World J Surg       Date:  2016-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.